Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients
Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients. // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000628?dgcid=rss_sd_all
Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients. International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000628?dgcid=rss_sd_all
“Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients.” International Journal of Lung Cancer.
@article{article107722,
title = {Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000628?dgcid=rss_sd_all}
}